PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin’s Lymphoma
Condition(s):Hodgkin Lymphoma, Adult; Relapse; Refractory Hodgkin LymphomaLast Updated:December 17, 2021Recruiting
Include Studies Not Open or Pending
Condition(s):Hodgkin Lymphoma, Adult; Relapse; Refractory Hodgkin LymphomaLast Updated:December 17, 2021Recruiting
Condition(s):Primary Malignant Neoplasm of Ovary; FIGO Stages II to IVLast Updated:June 10, 2014Recruiting
Condition(s):Healthy VolunteersLast Updated:March 4, 2024Not yet recruiting
Condition(s):MDS; AMLLast Updated:February 14, 2024Recruiting
Condition(s):Chronic Myeloid Leukemia in Myeloid Blast Crisis; Chronic Myeloid Leukaemia Transformation; Chronic Myeloid Leukemia – Accelerated Phase; Chronic Myeloid Leukemia in Lymphoid Blast CrisisLast Updated:December 8, 2022Recruiting
Condition(s):Hodgkin Lymphoma; Anti-PD-1 Antibody ResistantLast Updated:August 18, 2020Recruiting
Condition(s):Diffuse Large B Cell Lymphoma; Relapse/Recurrence; Extranodal Extension; Central Nervous System LymphomaLast Updated:May 9, 2023Recruiting
Condition(s):Acute Myeloid Leukemia; Myelodysplastic SyndromesLast Updated:September 1, 2023Recruiting
Condition(s):Objective Response RateLast Updated:June 9, 2021Recruiting
Condition(s):LeukemiaLast Updated:January 17, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.